Sign inJoin waitlistJoin the waitlist

YC

Yuanbin Chen

Physician · Orlando Health

Credentials: · · · · · · · ·

History

Orlando Health
2025–Present

Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2011–2014
Internal Medicine
1998–2001
Doctor of Medicine
1994–1998

Research

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label,…
The Lancet · 2019 · 1,945 citations
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
New England Journal of Medicine · 2023 · 739 citations
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN):…
The Lancet Oncology · 2021 · 600 citations

AT
Anish Thomas
10 papers
Vernon Sondak
9 papers
Jonathan Goldman
8 papers
Marina Garassino
7 papers
Jane Messina
6 papers
NK
Nikhil Khushalani
6 papers
ZE
Zeynep Eroglu
6 papers · 1 as a fellow
Afshin Dowlati
5 papers
Antoni Ribas
5 papers
DS
David Spigel
5 papers
Arun Rajan
4 papers
Charles Rudin
4 papers

Clinical trials

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2023–2031